Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells
- 10 January 2019
- journal article
- letter
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 54 (7), 1138-1140
- https://doi.org/10.1038/s41409-018-0423-y
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemiaJournal of Hematology & Oncology, 2017
- Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinomaJournal of Hematology & Oncology, 2017
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid TumorsCancer Research, 2016
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing CircuitsCell, 2016
- T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemiaCurrent Opinion in Hematology, 2015
- Remote control of therapeutic T cells through a small molecule–gated chimeric receptorScience, 2015
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemiaLeukemia, 2015
- Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trialsBlood Reviews, 2015
- PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy ResponsesScience Translational Medicine, 2013
- CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)Leukemia Research, 2013